Tirzepatide

Tirzepatide is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 8 labelled variants: 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 5mg, and 60mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, Tirzepatide sits alongside Retatrutide 30mg, GHK-CU, and BPC-157. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, Tirzepatide is generally treated as a dual-pathway incretin research analog associated with GIP and GLP-1 receptor studies. Its research background usually focuses on how dual receptor engagement affects assay design, pathway balance, and the interpretation of comparative signalling data.

This makes the material useful in laboratory discussions about receptor selectivity, comparator design, and sequence stability across multi-pathway test systems. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Tirzepatide behaves consistently across stability, purity, and analytical verification workflows. Representative catalogue identifiers on this page include TIRZEPATIDE-10MG, TIRZ-15MG, and TIRZEPATIDE-20MG, which supports clearer internal referencing when multiple labelled variants are under review.

A product-specific COA is linked on this page, with purity noted as 99.484%. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare Tirzepatide with Retatrutide 30mg, GHK-CU, and BPC-157, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.